Holen Sie sich die Stockscreener-App
10.85
0.09%
-0.0349
Artiva Biotherapeutics Inc Aktie (ARTV) Neueste Nachrichten
ARTV: Pivotal phase III trial for refractory RA advances, with robust enrollment and data updates expected - TradingView
Artiva Biotherapeutics CEO Aslan Fred Offloads 61,888 Shares at $11.16 on September 3, 2026 (NASDAQ: ARTV) - Kalkine Media
Artiva Biotherapeutics CTO Horan Christopher Disposes of 10,366 Shares at $11.16 Each (NASDAQ: ARTV) - Kalkine Media
Artiva initiates phase 3 trial for refractory arthritis therapy By Investing.com - Investing.com Canada
Artiva initiates phase 3 trial for refractory arthritis therapy - Investing.com
Artiva Biotherapeutics Announces Planned 2026 Data Readouts and Phase 3 Trial Initiation for AlloNK in Refractory Rheumatoid Arthritis - Quiver Quantitative
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026 - Yahoo! Finance Canada
Have Insiders Sold Artiva Biotherapeutics Shares Recently? - simplywall.st
Artiva Biotherapeutics CEO Fred Aslan Sells 61,888 Shares in Tax-Related Sell-to-Cover Transaction - Kalkine Media
Artiva Biotherapeutics COO Jennifer Bush Executes Share Sale for Tax Withholding Purposes - Kalkine Media
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying - Benzinga
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September - GlobeNewswire
Artiva Biotherapeutics CMO Subhashis Banerjee sells $98,735 in shares By Investing.com - Investing.com Australia
Artiva Biotherapeutics CMO Subhashis Banerjee Executes Stock Option Exercise and Sells Shares via 10b5-1 Plan - Kalkine Media
Artiva Biotherapeutics CMO Subhashis Banerjee sells $98,735 in shares - Investing.com
ARTV News | ARTIVA BIOTHERAPEUTICS INC (NASDAQ:ARTV) - ChartMill
ARTV Q2 2026 Earnings: Slightly Narrower Loss Delivers a Modest BeatOperating Income Trends - vinanet.vn
Artiva Biotherapeutics CMO Subhashis Banerjee disposes of 429 common shares worth $5,148 under 10b5-1 plan - Bitget
Artiva (ARTV) Earnings Update: The Bottom-Line Figure Outpaces Its Comparison on the Day; Post-Report: The Market Price Moves 0.17% Higher for the Current SessionEPS Revision Trend - vinanet.vn
Artiva Biotherapeutics CMO sells $5,148 in stock By Investing.com - Investing.com South Africa
Artiva Biotherapeutics CMO sells $5,148 in stock - Investing.com
Artiva Biotherapeutics: Targeting A Potentially Lucrative Niche (NASDAQ:ARTV) - Seeking Alpha
ARTV Q2 2026 Earnings: Narrower Loss of $0.63 per Share, But Stock Slips 0.35%Debt Analysis Report - vinanet.vn
What is HC Wainwright's Forecast for ARTV Q3 Earnings? - MarketBeat
Artiva Biotherapeutics (ARTV) Slips to $11.22 as Stock Holds Above Key SupportSmart Beta Flow - dars.gov.et
Artiva Biotherapeutics (ARTV) Edges Down 0.44% to $11.22, Trading Between Key Support and ResistanceVolatility Smile - dars.gov.et
Wall Street Zen Upgrades Artiva Biotherapeutics (NASDAQ:ARTV) to Hold - MarketBeat
TD Cowen Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Announces Target Price $11.58 - Moomoo
H.C. Wainwright Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $35 - Moomoo
ARTIVA BIOTHERAPEUTICS INC: QTRLY EPS $-0.63 - webull.com
Artiva Therapeutics: Buy Rating Reiterated on Strong AlloNK RA Profile and Upcoming Phase III, Price Target Maintained at $41 - TipRanks
Artiva Therapeutics: Buy Rating Reiterated on Promising RA Data, Clear Phase 3 Path and Maintained $35 Price Target - TipRanks
Certain Restricted Stock Units of Artiva Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-AUG-2026. - marketscreener.com
Certain Stock Options of Artiva Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-AUG-2026. - marketscreener.com
Artiva Biotherapeutics (NASDAQ:ARTV) Announces Quarterly Earnings Results - MarketBeat
Artiva Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
Artiva Biotherapeutics reports Q2 2026 net loss $25.0M, cash $349.4M to fund operations into 2029 - TradingView
FDA RMAT designation for AlloNK plus rituximab boosts Artiva Biotherapeutics, Inc. clinical progress - Traders Union
Artiva Biotherapeutics stock surges on positive trial data By Investing.com - Investing.com Nigeria
Form DEF 14A Artiva Biotherapeutics For: 3 August By Investing.com - Investing.com Nigeria
Ra capital management, 10% owner, acquires $455,725 Artiva stock - Investing.com
Form 4 Artiva Biotherapeutics Inc For: 1 August By Investing.com - Investing.com UK
Ra capital management, 10% owner, acquires $455,725 Artiva stock By Investing.com - Investing.com Canada
Artiva Biotherapeutics (NASDAQ:ARTV) Director Purchases $247,693.92 in Stock - MarketBeat
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Ra capital management director buys $412,776 in Artiva Biotherapeutics By Investing.com - Investing.com Nigeria
Form 4 Artiva Biotherapeutics Inc For: 28 July By Investing.com - Investing.com Canada
Artiva Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:ARTV - TradingView
RA Capital Management Boosts Artiva Biotherapeutics Stake with $412,000 Stock Acquisition - Kalkine Media
Artiva Biotherapeutics Inc (ARTV) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
Artiva Biotherapeutics Inc (ARTV) Cash Flow - TradingKey
ARTV|Artiva Biotherapeutics Inc|Price:10.340|Chg%:+0.310 - TradingKey
Artiva Biotherapeutics Inc (ARTV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Artiva Biotherapeutics Inc (ARTV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
Insider Stock Purchases: July 24, 2026 | ARTV Stock News - Quiver Quantitative
Thursday’s insider buys and sells: Artiva, StoneX and CoreWeave By Investing.com - Investing.com South Africa
Ra capital management, director, buys $58,306 of Artiva stock - Investing.com UK
ARTV Q1 2026 Earnings: EPS Miss Highlights Pre-Revenue Biotech's Cash Burn ChallengesEarnings Yield Spread - vinanet.vn
RA Capital Management acquires USD 2.62 million of Artiva Biotherapeutics common shares - Bitget
Form 4 Artiva Biotherapeutics Inc For: 23 July By Investing.com - Investing.com Nigeria
0.29%
4.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):